Insider trading allegations stall Sun–Ranbaxy deal


The merger deal that would create India’s largest pharmaceutical company has been stalled by accusations of insider trading of shares in the lead-up to the takeover announcement. The High Court of Andhra Pradesh has halted the transaction between Sun Pharma and Ranbaxy while the allegations are investigated.

The allegations centre on an unusually rapid increase in Ranbaxy’s share price in the week before the deal was announced. Sun Pharma has denied any wrongdoing, saying in a statement that: ‘The matter related to purchase of shares of Ranbaxy Laboratories does not violate insider trading rules.’


Related Content

Sun Pharma snares Ranbaxy in $4bn deal

1 April 2015 Business

news image

Acquisition makes Sun biggest drug firm in India and fifth largest generics producer in the world

Sun set on Ranbaxy rescue

9 April 2014 Business

news image

Acquiring beleaguered firm will create India’s biggest pharmaceutical company

Most Read

Super-elastic wire stretches without losing power

23 July 2015 Research

news image

Fibre that can stretch 14 times its own length could find its way into robotic arms and satellites

Weaving is believing

23 July 2015 The Crucible

news image

Philip Ball unpicks the history of science’s woollen wardrobe

Most Commented

Weaving is believing

23 July 2015 The Crucible

news image

Philip Ball unpicks the history of science’s woollen wardrobe

Despair and anger among Greek scientists at universities' finances

17 July 2015 News and Analysis

news image

Little hope that billions of euros in new loans from the EU will improve the situation